Argentina joined Peru, Morocco and the United Arab Emirates to approve phase 3 clinical trials of a coronavirus vaccine developed through China’s National Biotec Group (CNBG), the corporation announced friday.
As China advances the global race to expand a vaccine to curb the COVID-19 pandemic and instances in China decline, CNBG wants participants to look for other countries for testing.
Read the updates in our coronavirus section.
Phase 3 trials, involving several thousand participants, allow researchers to gather knowledge about the effectiveness of prospective vaccines for final regulatory approvals.
Read more:
Coronavirus: WHO starts talks with Russia on COVID-19 vaccine
The G42 of the United Arab Emirates will paint with Israeli NanoScent to expand a COVID-19 perfume detector
CNBG will be part of the ELEA of Argentina as a component of the vaccine trial, announced by the Chinese company on Friday night.
For all newer titles, stay on our Google News channel online or in the app.